Question from Deputy Ken O’Flynn - PQ 43627 26
Deputy O'Flynn asked if there has been a review into the drivers of variation in reimbursement costs for salbutamol nebule products. Read the HSE response.
From: Communications and public affairs
Published: June 2026
Updated: July 2026
Documents
Summary
To ask the Minister for Health whether any review, analysis, assessment, briefing, report, business case, internal examination or other evaluation has been undertaken since 1 January 2024 regarding the drivers of variation in reimbursement costs for salbutamol nebule products under the General Medical Services Scheme; if so, to provide the date, author, purpose and principal findings of each such review; and if no such review has been undertaken, to confirm that fact.
This is a beta version - your feedback will help us to improve it